Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2002;106:2132-2136
Published online before print September 23, 2002, doi: 10.1161/01.CIR.0000033596.21845.D8
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
106/16/2132    most recent
01.CIR.0000033596.21845.D8v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pham, T. V.
Right arrow Articles by Rosen, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pham, T. V.
Right arrow Articles by Rosen, M. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ESTRADIOL
Related Collections
Right arrow Animal models of human disease
Right arrow Arrythmias-basic studies
Right arrow Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2002;106:2132.)
© 2002 American Heart Association, Inc.


Basic Science Reports

Testosterone Diminishes the Proarrhythmic Effects of Dofetilide in Normal Female Rabbits

Thai V. Pham, PhD; Eugene A. Sosunov, PhD; Evgeny P. Anyukhovsky, PhD; Peter Danilo, Jr, PhD; Michael R. Rosen, MD

From the Department of Molecular and Cellular Pharmacology, University of Miami School of Medicine, Miami, Fla (T.V.P.), and the Departments of Pharmacology (E.A.S., E.P.A., P.D., M.R.R.) and Pediatrics (M.R.R.) and the Center for Molecular Therapeutics (P.D., M.R.R.), College of Physicians and Surgeons of Columbia University, New York, NY.

Correspondence to Michael R. Rosen, MD, Director, Center for Molecular Therapeutics, Gustavus A. Pfeiffer Professor of Pharmacology, Professor of Pediatrics, Department of Pharmacology, College of Physicians and Surgeons of Columbia University, 630 W 168 St, PH7West-321, New York, NY 10032. E-mail mrr1{at}columbia.edu

Background— Recent clinical and experimental data suggest that testosterone may protect males against the deleterious effects of repolarization-prolonging drugs. This study tests the hypothesis that 5{alpha}-dihydrotestosterone (DHT) protects normal females against drug-induced excessive prolongation of repolarization.

Methods and Results— We used microelectrode techniques to study isolated preparations of rabbit ventricular endocardium from age-matched normal control female rabbits and female rabbits treated with DHT for 4 weeks. Serum 17ß-estradiol levels were identical in the control and DHT-treated animals, whereas DHT levels were high (equaling those in normal males) only in the DHT-treated animals. Basal action potential duration to 90% repolarization (APD90) was significantly shorter in DHT-treated (155±7.4 ms, n=32) than control females (178±6.7 ms, n=29; P<0.05) at cycle length=1000 ms. The increase in APD90 induced by 10-8 mol/L dofetilide at cycle length=1000 ms was significantly less in DHT-treated females than normal females ({Delta}APD90=8±7 and 29±5 ms, respectively, P<0.05). At 10-6 mol/L dofetilide, the incidence of early afterdepolarizations was 28% in DHT-treated and 55% in normal female rabbits (P<0.05).

Conclusions— Elevating DHT levels diminishes the effects of dofetilide to increase APD and induce early afterdepolarizations in females. Moreover, treatment of females with DHT results in prolongation of APD and an incidence of early afterdepolarization equal to values previously reported by us for dofetilide-treated normal males. That serum levels of 17ß-estradiol were the same in DHT-treated and untreated females suggests that estradiol is not involved in the response to dofetilide. Thus, these data suggest that DHT and perhaps other androgenic hormones may protect normal females against the risk of dofetilide-induced arrhythmia.


Key Words: arrhythmia • sex • dofetilide • hormones




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. Xiao, L. Zhang, W. Han, Z. Wang, and S. Nattel
Sex-based transmural differences in cardiac repolarization and ionic-current properties in canine left ventricles
Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H570 - H580.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C.-X. Bai, J. Kurokawa, M. Tamagawa, H. Nakaya, and T. Furukawa
Nontranscriptional Regulation of Cardiac Repolarization Currents by Testosterone
Circulation, September 20, 2005; 112(12): 1701 - 1710.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Brouillette, K. Rivard, E. Lizotte, and C. Fiset
Sex and strain differences in adult mouse cardiac repolarization: importance of androgens
Cardiovasc Res, January 1, 2005; 65(1): 148 - 157.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
D. M. Roden
Drug-Induced Prolongation of the QT Interval
N. Engl. J. Med., March 4, 2004; 350(10): 1013 - 1022.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. V Pham
Gender differences in cardiac development: are hormones at the heart of the matter?
Cardiovasc Res, March 1, 2003; 57(3): 591 - 593.
[Full Text] [PDF]